Interim Condensed Consolidated Financial Statements - Additional Information (Detail) - USD ($) $ in Millions	1 Months Ended	6 Months Ended
Sep. 30, 2013	Jun. 30, 2016
Merck Kgaa [Member]
Condensed Financial Statements, Captions [Line Items]
Revenue recognition, recorded revenue cost plus percentage		20.00%
Additional license and supply agreement renewals term		5 years
License and supply agreement expiration date		May 19, 2020
Juniper Pharma Services [Member]
Condensed Financial Statements, Captions [Line Items]
Assumed obligation under grant arrangement by the entity	$ 3.9
Juniper Pharma Services [Member] \| Regional Growth Fund [Member]
Condensed Financial Statements, Captions [Line Items]
Assumed obligation under grant arrangement by the entity	$ 2.5	$ 2.5

Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6578-128477

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6613-128477

Name:	us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration